about
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesAutoimmune markers in children with chronic pancreatitis.Gene conversion between cationic trypsinogen (PRSS1) and the pseudogene trypsinogen 6 (PRSS3P2) in patients with chronic pancreatitis.Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Variants in CPA1 are strongly associated with early onset chronic pancreatitis.Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.The Etiology and Clinical Course of Chronic Pancreatitis in Children With Early Onset of the Disease.The clinical course of hereditary pancreatitis in children - A comprehensive analysis of 41 cases.Evaluation of the effectiveness of biofeedback therapy for functional constipation in children.The TUBEX typhoid test detects current Salmonella infections.The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.EPC/HPSG evidence-based guidelines for the management of pediatric pancreatitis.Nontyphoid salmonellosis in Polish children.Rapid diagnosis of acute Salmonella gastrointestinal infection.Chymotrypsinogen C Genetic Variants, Including c.180TT, Are Strongly Associated With Chronic Pancreatitis in Pediatric Patients.Efficiency of pancreatic duct stenting therapy in children with chronic pancreatitis.Pediatric Acute and Chronic Pancreatitis: Increase in Incidence or Increasing Awareness?MRCP Versus ERCP in the Evaluation of Chronic Pancreatitis in Children: Which Is the Better Choice?Is Chronic Pancreatitis in Children an Autoimmune Disease?Guidelines for diagnosis and treatment of chronic pancreatitis. Recommendations of Working Group of the Polish National Consultant in gastroenterology and Polish Pancreatic ClubA clinical characteristic of paediatric ulcerative colitis patients qualified for a Cyclosporin A therapyA novel p.Ser282Pro variant is associated with autosomal dominant hereditary pancreatitisComplications of endoscopic retrograde cholangiopancreatography in children with chronic pancreatitis depends on center experienceSwitching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary ObservationsToxic-metabolic Risk Factors in Pediatric Chronic Pancreatitis—Single Center ExperienceThe nutritional status and factors contributing to malnutrition in children with chronic pancreatitisNon-invasive evaluation mucosal inflammation in inflammatory bowel diseases in childrenMaintenance therapy with infliximab for paediatric Crohn’s disease: impact on clinical remission and mucosal healing in Polish paediatric patients with severe Crohn’s diseaseThe clinical course of chronic pancreatitis associated with lipid disturbances in childrenAssessment of nutritional status of children with portal hypertensionOral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowthAnalysis of CFTR, SPINK1, PRSS1 and AAT Mutations in Children With Acute or Chronic Pancreatitis
P50
Q28066776-A5083193-ABF7-4691-8878-7300482BC635Q33947438-4656F132-1E66-4A6C-959A-BDF8101A9EF1Q35181335-C90EEC5B-BA00-4E5D-B450-53CCD8B61FBDQ36167373-C79389A3-6F6C-4781-94E8-E57C0BD2D458Q37540036-885DE03E-540F-4B9A-A580-CF6C3B2A559FQ38202595-C0910617-86D1-47A9-BF6C-9DF2BF0D7824Q38765158-4CDDA787-2D03-4055-83BC-4C4747AA4535Q39347254-782267DA-F68F-4333-93D0-CB263E3D591EQ39765913-083427F9-C928-47DF-85C8-1FDBCFD843CAQ43355820-2A0D0B76-6790-49EA-937F-94BF40606FAAQ44705585-D395F3C8-593D-41D6-8155-AD9D18B27B1FQ45326208-9F766059-2BF2-4556-BC93-2E00ED130701Q49342414-084D6C10-9F5D-425F-93CC-720C2743847BQ50093385-67A49E40-2F1E-4A12-AF49-97CC6A2BEF72Q50106144-9200CA78-EF8C-475E-BA57-2122ADBC3505Q50264540-68795659-D817-4C3C-97DA-A3C7D496FB20Q53544690-F6B59ADD-E9A9-47C1-8E4E-13551F4AE6BDQ53716157-625C4B3F-57EE-4476-B1F1-351F1C12B3B8Q54612504-9049ECAE-3AEC-48D0-8651-BA57AE5137E0Q58236989-2804BAEA-FE6F-4CCC-8E06-56A64001A94AQ60609716-9ACE38D6-C667-4AEC-9EE1-FD26C940EE42Q60609831-59B65130-0379-4BDA-ACCC-611A2795E960Q60609832-6C627857-A157-426B-8DEF-1AE8E81EC402Q60609833-C47452D6-B619-4D70-ACE6-40EA5A6DACADQ60609835-38642ABB-B5E9-4BA3-AFEE-54E640EC52F8Q60609836-8CC379B0-9CAE-4A6C-9585-D26D42A5DB70Q60609837-3C3FEC81-D460-4EA4-B4EF-81E8AA5BB52EQ60609839-505F03E4-5F35-493F-989F-05E2A8913DDAQ60609840-3DDBC31C-BF56-4F20-8899-1D93EC78807BQ60609841-F005ED56-A67B-482C-8365-84DC9E5F1181Q60609842-6BACE795-E21C-47B7-AEA9-2958CC62DAC4Q60609844-50ABA4AB-71E7-4053-BC18-2204BBB003B8Q60609845-E7AB1DF2-5264-464A-AF60-9338D2EFF686
P50
description
researcher, ORCID id # 0000-0003-1938-7519
@en
wetenschapper
@nl
name
Grzegorz Oracz
@ast
Grzegorz Oracz
@en
Grzegorz Oracz
@es
Grzegorz Oracz
@nl
type
label
Grzegorz Oracz
@ast
Grzegorz Oracz
@en
Grzegorz Oracz
@es
Grzegorz Oracz
@nl
prefLabel
Grzegorz Oracz
@ast
Grzegorz Oracz
@en
Grzegorz Oracz
@es
Grzegorz Oracz
@nl
P214
P106
P1153
6602259171
P21
P214
P31
P496
0000-0003-1938-7519
P735
P7859
viaf-286522176